NRIX

Nurix Therapeutics, Inc.

NasdaqGMUSDEQUITY DELAYED

26.72

▼ 0.33 (1.22%)

MARKET · —

Price

Open

27.10

Prev close

27.05

Day high

27.50

Day low

26.70

Volume

1.49M

Market cap

—

P/E (TTM)

—

52W range

8.20 – 28.23

Trailing performance

Price return · vs SPY

Returnvs SPY

-1.22% +0.1%

+12.55% +8.8%

+52.42% +49.3%

+69.33% +58.3%

YTD

+40.85% +28.6%

+180.38% +160.4%

+210.70% +136.5%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

26.84

-0.44% from price

SMA 20

25.51

+4.76% from price

SMA 50

23.28

+14.76% from price

SMA 100

19.83

+34.76% from price

SMA 200

18.22

+46.66% from price

EMA 12

26.46

+0.98% from price

EMA 26

25.26

+5.79% from price

EMA 50

23.47

+13.84% from price

RSI (14)

63.8

Neutral

MACD (12,26,9)

1.20

Hist 0.01

ATR (14)

0.98

3.66% of price

Realised vol 30D

33.1%

Annualised

Bollinger upper

28.53

20, 2σ

Bollinger lower

22.49

20, 2σ

50 / 200 cross

Golden

23.28 vs 18.22

Trend bias

Above 200

+46.66%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.51

More volatile than market

Correlation to SPY

0.32

Loosely linked

Realised vol 30D

33.1%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-32.8%

Peak to trough

Max drawdown 5Y

-88.4%

Peak to trough

ATR 14

0.98

3.66% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 26.72

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

NRIX · links out to the publisher

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer GlobeNewswire · 2d ago Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says MT Newswires · 12d ago RBC Adjusts PT on Nurix Therapeutics to $36 From $33, Maintains Outperform Speculative Risk Rating MT Newswires · 12d ago Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins Simply Wall St. · 17d ago Nurix Therapeutics Gets $10 Million Milestone Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader MT Newswires · 18d ago Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader GlobeNewswire · 18d ago Nurix Therapeutics Enrolls First Patient in Phase 3 Blood Cancer Trial MT Newswires · 18d ago Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma GlobeNewswire · 18d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.